BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

AMTD Digital, Inc. is a holding company, which engages in the development of digital solutions applications under AMTD SpiderNet platform. It operates through the following segments: Digital Solutions Services-Non Financial Services; Digital Solutions Services-Financial Services; Hotel Operations, Hospitality, and VIP Services; and Digital Media, Content, and Marketing Services, and Others. The Digital Solutions Services-Non Financial Services segment offers paid access to the AMTD SpiderNet ecosystem for investor communications, investor relations, and corporate communications. The Digital Solutions Services-Financial Services segment provides insurance brokerage services. The Hotel Operations, Hospitality, and VIP Services segment is associated with hotel investments and related services. The Digital Media, Content, and Marketing Services, and Others segment promotes digital solutions and digital medium through a library of digital videos and online media platforms. The company was founded on September 12, 2019 and is headquartered in Paris, France.

Hitek Global, Inc. is a holding company, which engages in the provision of information technology consulting and solutions. It operates through the services to small and medium businesses, which consists of anti-counterfeiting tax control system tax devices, golden tax disk and printers, and information technology services; and services to hardware and software sales business lines. The company was founded by Shen Ping Yin on November 3, 2017 and is headquartered in Xiamen, China.

Brookfield Renewable Corp. engages in the ownership and operation of a portfolio of renewable power and sustainable solution assets. Its portfolio includes hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia. Its businesses include renewable power and transition, infrastructure, private equity, real estate, and credit and insurance solutions. The company was founded on September 9, 2019 and is headquartered in New York, NY.

Cambium Networks Corp. engages in the provision of wireless broadband networking infrastructure solutions for network operators. Its products include point-to-point, enterprise Wi-Fi and switching, CCTV,software, and point-to multipoint. The company was founded in 2011 and is headquartered in Rolling Meadows, IL.

Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices helps people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.

LanzaTech Global, Inc. engages in the provision of nature-based carbon refining that transforms waste carbon into chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging. The company is headquartered in Skokie, IL.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

AGBA Group Holding Ltd. is a wealth and health platform, which engages in the activities span a business-to-business platform, healthcare and wellness services, fintech businesses, as well as financial advisory services. It operates through the following business segments: Distribution Business, Platform Business, Fintech Business, and Healthcare Business. The Distribution Business segment facilitates the placement of insurance, investment, real estate and other financial products and services to the customers, through licensed brokers, in exchange for initial and ongoing commissions. The Platform Business segment provides access to financial products and services to licensed brokers. The Fintech Business segment focuses on the ensemble of fintech investments. The Healthcare Business segment manages an ensemble of healthcare-related investments. The company was founded in 2018 and is headquartered in Hong Kong.